AstraZeneca Pharmaceuticals (China) Co., Ltd.

AstraZeneca is a top-tier pharmaceutical company formed in 1999 through the merger of the former Swedish company Astra and the former British company Zeneca. As a global innovation-driven biopharmaceutical enterprise, AstraZeneca's global headquarters is in London, UK, with approximately 61,500 employees worldwide, operations in over 100 countries, and production facilities in 17 countries.
Its three strategic R&D centers are located in Cambridge, UK; Gaithersburg, Maryland, USA; and Mölndal, Sweden, with annual R&D investment exceeding $4 billion.
Since entering China in 1993, AstraZeneca has adhered to science-first principles and emphasized innovation to meet China's growing medical needs, striving towards the ambitious vision of "Pioneering innovation, benefiting patients, and becoming a trusted healthcare partner in China." AstraZeneca's China headquarters is in Shanghai, with over 10,000 employees nationwide and sales of $2.96 billion in China in 2017. The company has invested over $750 million in China, with production bases in Wuxi and Taizhou, and a China logistics center in Wuxi. In China, AstraZeneca's business focuses on therapeutic areas needed by Chinese patients, including cardiovascular, metabolic diseases, oncology, respiratory, digestive, and anesthesia.